British Columbia Investment Management’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-151,100
Closed -$16.8M 845
2021
Q1
$16.8M Buy
151,100
+22,100
+17% +$2.73M 0.12% 162
2020
Q4
$15.3M Hold
129,000
0.11% 154
2020
Q3
$11.3M Hold
129,000
0.09% 192
2020
Q2
$11.6M Buy
129,000
+45,200
+54% +$4.57M 0.11% 160
2020
Q1
$8.35M Buy
83,800
+56,700
+209% +$6.15M 0.14% 132
2019
Q4
$3.11M Buy
+27,100
New +$3.28M 0.02% 528

Other funds holding HAE

British Columbia Investment Management's HAE Position: Q2 2021 in Review

British Columbia Investment Management sold out of Haemonetics (HAE) in Q2 2021, closing a stake of 151,100 shares — an estimated $16.8M sold.

British Columbia Investment Management first reported a position in HAE in Q4 2019 and held it in 6 quarters. The position peaked at $16.8M in Q1 2021. 258 funds tracked by Wall St. Rank hold HAE as of Q2 2021.

  • British Columbia Investment Management reported no remaining Haemonetics position as of Q2 2021 after selling out during the quarter.
  • British Columbia Investment Management sold 151,100 Haemonetics shares in Q2 2021, an estimated $16.8M.
  • British Columbia Investment Management first reported a position in Haemonetics in Q4 2019 and held it in 6 quarters.
  • British Columbia Investment Management's Haemonetics position peaked at $16.8M in Q1 2021.
  • 258 funds tracked by Wall St. Rank held Haemonetics as of Q2 2021.

Based on British Columbia Investment Management's 13F filing for Q2 2021, filed 9 Aug 2021.